Adlai Nortye (NASDAQ:ANL) Stock Price Down 8% – Here’s What Happened

Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) dropped 8% during trading on Wednesday. The company traded as low as $8.51 and last traded at $8.72. 141,453 shares traded hands during trading, a decline of 60% from the average session volume of 356,535 shares. The stock had previously closed at $9.48.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Adlai Nortye in a report on Tuesday, September 8th. Jefferies Financial Group raised Adlai Nortye to a “strong-buy” rating in a research report on Monday, October 5th. Loop Capital set a $49.00 target price on shares of Adlai Nortye in a research report on Tuesday, September 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Adlai Nortye in a research note on Monday, October 12th. Finally, Wall Street Zen downgraded shares of Adlai Nortye from a “buy” rating to a “hold” rating in a research report on Saturday, October 31st. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

View Our Latest Research Report on ANL

Adlai Nortye Price Performance

The firm’s 50 day moving average price is $12.56 and its 200-day moving average price is $11.69.

Insider Activity

In other news, Director Ping Ji sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $15.99, for a total value of $159,900.00. Following the sale, the director directly owned 121,453 shares in the company, valued at approximately $1,942,033.47. This represents a 7.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Xiaofeng Ye sold 5,667 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total value of $80,754.75. Following the completion of the sale, the chief financial officer owned 147,757 shares in the company, valued at $2,105,537.25. This trade represents a 3.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 26,881 shares of company stock valued at $411,060.

Institutional Trading of Adlai Nortye

Several large investors have recently made changes to their positions in the business. Soleus Capital Management L.P. grew its position in shares of Adlai Nortye by 213.8% during the 3rd quarter. Soleus Capital Management L.P. now owns 1,272,355 shares of the company’s stock worth $20,358,000 after buying an additional 866,832 shares during the period. Braidwell LP acquired a new position in shares of Adlai Nortye during the second quarter worth about $9,145,000. Boone Capital Management LLC bought a new position in shares of Adlai Nortye during the 2nd quarter worth approximately $2,971,000. Seven Fleet Capital Management LP acquired a new stake in Adlai Nortye in the 2nd quarter valued at $1,302,000. Finally, Marshall Wace LLP increased its position in shares of Adlai Nortye by 60.1% in the third quarter. Marshall Wace LLP now owns 76,210 shares of the company’s stock valued at $1,219,000 after acquiring an additional 28,614 shares during the last quarter. Institutional investors own 35.21% of the company’s stock.

Adlai Nortye Company Profile

(Get Free Report)

Adlai Nortye is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2004 and headquartered in Hangzhou, China, the company conducts drug research and development for potential use in China and international markets. Its investigational oncology pipeline includes AN2025, a pan-RAF inhibitor; AN0025, an EP4 antagonist; and AN4005, an adenosine A2A/A2B receptor antagonist. These candidates are being studied for their potential to treat solid tumors, including in combination with other cancer therapies.

Further Reading

Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.